Chochi Kentaro, Ichikura Takashi, Kinoshita Manabu, Majima Takashi, Shinomiya Nariyoshi, Tsujimoto Hironori, Kawabata Toshinobu, Sugasawa Hidekazu, Ono Satoshi, Seki Shuhji, Mochizuki Hidetaka
Department of Surgery, National Defense Medical College, Namiki, Tokorozawa, Japan.
Clin Cancer Res. 2008 May 15;14(10):2909-17. doi: 10.1158/1078-0432.CCR-07-4467.
Helicobacter pylori is reportedly involved in the development of gastric cancer. We investigated the mechanisms by which H. pylori affects gastric cancer growth and antitumor immunities in the host, focusing on H. pylori-derived lipopolysaccharide (LPS).
H. pylori and four gastric cancer cell lines (MKN28, MKN45, NUGC3, and KATOIII) were used. We examined the effect of H. pylori or its LPS stimulation on cancer growth and the involvement of the H. pylori LPS-toll-like receptor 4 (TLR4) pathway. We also examined the cytotoxicities of H. pylori/LPS-stimulated human mononuclear cells (MNC) against gastric cancer cells and the effect of H. pylori LPS stimulation on cytokine production by MNC.
H. pylori, as well as its LPS, augmented the growth of gastric cancers, all of which expressed TLR4. Neutralization of TLR4 almost completely abrogated the H. pylori-induced proliferative activity of cancer cells. Escherichia coli LPS also augmented cancer growth via the LPS-TLR4 pathway. However, only H. pylori-derived LPS attenuated the cytotoxicity of MNC against gastric cancer cells. Stimulation with H. pylori/LPS also down-regulated perforin production in cancer cell-cocultured CD56+ natural killer cells. H. pylori LPS induced neither interleukin-12 nor IFN-gamma production by MNC, although E. coli LPS did induce production of both significantly. Nevertheless, interleukin-12 stimulation restored the IFN-gamma-producing capacity of H. pylori LPS-stimulated MNC.
H. pylori augmented the growth of gastric cancers via the LPS-TLR4 pathway, whereas it attenuated the antitumor activity and IFN-gamma-mediated cellular immunity of MNC. H. pylori infection might thereby promote proliferation and progression of gastric cancers.
据报道,幽门螺杆菌与胃癌的发生发展有关。我们研究了幽门螺杆菌影响胃癌生长及宿主抗肿瘤免疫的机制,重点关注幽门螺杆菌衍生的脂多糖(LPS)。
使用幽门螺杆菌和四种胃癌细胞系(MKN28、MKN45、NUGC3和KATOIII)。我们研究了幽门螺杆菌或其LPS刺激对癌症生长的影响以及幽门螺杆菌LPS- Toll样受体4(TLR4)途径的参与情况。我们还研究了幽门螺杆菌/LPS刺激的人单核细胞(MNC)对胃癌细胞的细胞毒性以及幽门螺杆菌LPS刺激对MNC细胞因子产生的影响。
幽门螺杆菌及其LPS均促进了胃癌的生长,所有胃癌细胞均表达TLR4。TLR4的中和几乎完全消除了幽门螺杆菌诱导的癌细胞增殖活性。大肠杆菌LPS也通过LPS-TLR4途径促进癌症生长。然而,只有幽门螺杆菌衍生的LPS减弱了MNC对胃癌细胞的细胞毒性。幽门螺杆菌/LPS刺激还下调了与癌细胞共培养的CD56 +自然杀伤细胞中穿孔素的产生。幽门螺杆菌LPS既不诱导MNC产生白细胞介素-12也不诱导产生干扰素-γ,尽管大肠杆菌LPS确实显著诱导了两者的产生。然而,白细胞介素-12刺激恢复了幽门螺杆菌LPS刺激的MNC产生干扰素-γ的能力。
幽门螺杆菌通过LPS-TLR4途径促进胃癌生长,而减弱了MNC的抗肿瘤活性和干扰素-γ介导的细胞免疫。因此,幽门螺杆菌感染可能促进胃癌的增殖和进展。